Amphastar Pharmaceuticals, Inc. (AMPH) Gross Margin
- Gross margin · 12 months: Value 47.68%; Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | 47.68% | Gross profit / revenue. Period ending 2026-06-30. $348.11M ÷ $730.02M × 100 ≈ 47.68% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | 348.11M USD | Gross Profit |
| Revenue | 730.02M USD | |
| Cost of products and services | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | $348.11M | $730.02M | (m) | 47.68% |
| 2026-03-31 | $341.13M | $720.53M | (m) | 47.34% |
| 2025-12-31 | $356.06M | $719.89M | (m) | 49.46% |
| 2025-09-30 | $357.04M | $723.30M | (m) | 49.36% |
| 2025-06-30 | $360.33M | $722.68M | (m) | 49.86% |
| 2025-03-31 | $369.01M | $730.66M | (m) | 50.50% |
| 2024-12-31 | $373.86M | $731.97M | (m) | 51.08% |
| 2024-09-30 | $383.35M | $723.55M | (m) | 52.98% |
| 2024-06-30 | $389.81M | $712.89M | (m) | 54.68% |
| 2024-03-31 | $367.38M | $676.21M | (m) | 54.33% |
| 2023-12-31 | $351.12M | $644.39M | (m) | 54.49% |
| 2023-09-30 | $326.15M | $601.31M | (m) | 54.24% |
| 2023-06-30 | $276.26M | $540.89M | (m) | 51.07% |
| 2023-03-31 | $266.87M | $518.64M | (m) | 51.46% |
| 2022-12-31 | $248.86M | $498.99M | (m) | 49.87% |
| 2022-09-30 | $233.93M | $484.85M | (m) | 48.25% |
| 2022-06-30 | $226.60M | $476.92M | (m) | 47.51% |
| 2022-03-31 | $210.62M | $455.12M | (m) | 46.28% |
| 2021-12-31 | $199.74M | $437.77M | (m) | 45.63% |
| 2021-09-30 | $180.34M | $412.80M | (m) | 43.69% |
| 2021-06-30 | $165.66M | $384.04M | (m) | 43.14% |
| 2021-03-31 | $151.46M | $368.18M | (m) | 41.14% |
| 2020-12-31 | $143.34M | $349.85M | (m) | 40.97% |
| 2020-09-30 | $139.89M | $337.31M | (m) | 41.47% |
| 2020-06-30 | $138.63M | $334.01M | (m) | 41.51% |
| 2020-03-31 | $137.84M | $327.25M | (m) | 42.12% |
| 2019-12-31 | $131.92M | $322.36M | (m) | 40.92% |
| 2019-09-30 | $133.23M | $328.66M | (m) | 40.54% |
| 2019-06-30 | $127.24M | $324.07M | (m) | 39.26% |
| 2019-03-31 | $120.92M | $316.06M | (m) | 38.26% |
| 2018-12-31 | $106.98M | $294.67M | (m) | 36.31% |
| 2018-09-30 | $93.07M | $265.38M | (m) | 35.07% |
| 2018-06-30 | $84.44M | $247.75M | (m) | 34.08% |
| 2018-03-31 | $85.03M | $241.90M | (m) | 35.15% |
| 2017-12-31 | $90.80M | $240.18M | (m) | 37.80% |
| 2017-09-30 | $90.18M | $243.32M | (m) | 37.06% |
| 2017-06-30 | $97.15M | $249.62M | (m) | 38.92% |
| 2017-03-31 | $102.11M | $252.47M | (m) | 40.45% |
| 2016-12-31 | $104.19M | $255.16M | (m) | 40.83% |
| 2016-09-30 | $117.40M | $268.53M | (m) | 43.72% |
| 2016-06-30 | $107.36M | $268.18M | (m) | 40.03% |
| 2016-03-31 | $88.97M | $254.00M | (m) | 35.03% |
| 2015-12-31 | $77.35M | $251.52M | (m) | 30.75% |
| 2015-09-30 | $56.14M | $230.48M | (m) | 24.36% |
| 2015-06-30 | $50.35M | $226.33M | (m) | 22.25% |
| 2015-03-31 | $52.03M | $221.48M | (m) | 23.49% |
| 2014-12-31 | $51.26M | $210.46M | (m) | 24.35% |
| 2014-09-30 | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) |
| 2014-03-31 | $79.91M | $222.59M | (m) | 35.90% |
| 2013-12-31 | $86.96M | $229.68M | (m) | 37.86% |
| 2013-09-30 | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | (m) | (m) |
| 2012-12-31 | $90.30M | $204.32M | (m) | 44.20% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |